Status:
COMPLETED
Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Japan. This a clinical trial to study the efficacy and safety of three times a day BIAsp-70 compared to two times a day BIAsp-30 in subjects with type 2 diabetes.
Eligibility Criteria
Inclusion
- Subjects with type 2 diabetes
- Current treatment using intermediate-acting, long-acting insulin (including long-acting insulin analogue) or pre-mixed human insulin for at least 24 weeks
- HbA1c at least 7.5% and below 10.0%
Exclusion
- Proliferative retinopathy or maculopathy requiring acute treatment
- Impaired hepatic and/or renal function
- Cardiac diseases
- Uncontrolled hypertension
- Known hypoglycemia unawareness or recurrent major hypoglycemia
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
289 Patients enrolled
Trial Details
Trial ID
NCT00318786
Start Date
April 1 2006
End Date
June 1 2007
Last Update
January 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005